Tortoise Pipeline & Energy Fund Inc (NYSE:TTP)

$ 33.84 -0.39 (-1.14%) Market Cap: 68.04 Mil Enterprise Value: 77.88 Mil PE Ratio: 15.31 PB Ratio: 0.98 GF Score: 40/100

Q3 2020 Titan Pharmaceuticals Inc Earnings Call Transcript
Nov 16, 2020

$13.94 (+4.81%)

Earnings
Q2 2020 Titan Pharmaceuticals Inc Earnings Call Transcript
Aug 14, 2020

$15.02 (+0.67%)

Earnings
Q1 2020 Titan Pharmaceuticals Inc Earnings Call Transcript
May 15, 2020

$14.03 (+4.94%)

Earnings
Q4 2019 Titan Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2020

$10.08 (-4.55%)

Earnings
Q3 2019 Titan Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2019

$47.8 (-2.05%)

Earnings
Q2 2019 Titan Pharmaceuticals Inc Earnings Call Transcript
Aug 14, 2019

$50.19 (-2.96%)

Earnings
Q1 2019 Titan Pharmaceuticals Inc Earnings Call Transcript
May 15, 2019

$61.36 (+0.13%)

Earnings
Q4 2018 Titan Pharmaceuticals Inc Earnings Call Transcript
Apr 02, 2019

$62.2 (+0.78%)

Earnings

Q4 2018 Titan Pharmaceuticals Inc Earnings Call Transcript

Apr 02, 2019 / 12:30PM GMT

Release Date Price: $62.2 (+0.78%)

Transcript

Operator

Thank you for holding, and welcome to the Titan Pharmaceuticals Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions). Please be advised that this call is being taped at company's request and will be archived on the company's website starting later today. At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. Please go ahead.

Sunil Bhonsle

Titan Pharmaceuticals, Inc. - President, CEO, Principal Financial Officer & Director

Thank you, Anita, and thank you all for joining us. Welcome to the Titan Pharmaceuticals call to review financial and operational results for the fourth quarter and year ended December 31, 2018, and we'll provide an update on our business.

Before we begin, I wanted to inform you that we filed our 2018 annual report on Form 10-K yesterday with the SEC and amended it with a correction this morning, and the press release issued provides a summary of the results and can be found on our website at titanpharm.com.

Joining me on the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.